ArticleBio-protocol2018
CRISPR/Cas Gene Editing of a Large DNA Virus: African Swine Fever Virus.
Article in Bio-protocol, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 45 citations in OpenAlex.
- Evaluation of Cryopreserved Primary Swine Macrophages as a Substrate for African Swine Fever Virus Replication.Methods and protocols · 2026Article
- African swine fever vaccine ASFV-G-ΔI177L induces solid protection in four-week-old piglets.Scientific reports · 2025Article
- The First CRISPR-Based Therapeutic (SL_1.52) for African Swine Fever Is Effective in Swine.Viruses · 2025Article
- Lyophilization of ASFV vaccine candidate ASFV-G-ΔI177L offers long term stability.Scientific reports · 2024Article
- Article
- Article
- Article
- Article
- Near-complete genome sequences of multiple genotype 1 African swine fever virus isolates from 2016 to 2018 in Cameroon.Microbiology resource announcements · 2024Article
- Article
- Unexpected thermal stability of two enveloped megaviruses, Emiliania huxleyi virus and African swine fever virus, as measured by viability PCR.Virology journal · 2024Article
- The 2022 Outbreaks of African Swine Fever Virus Demonstrate the First Report of Genotype II in Ghana.Viruses · 2023Article
- Exploring the Molecular Basis of Vesicular Stomatitis Virus Pathogenesis in Swine: Insights from Expression Profiling of Primary Macrophages Infected with M51R Mutant Virus.Pathogens (Basel, Switzerland) · 2023Article
- Deletion of theViruses · 2023Article
- Evaluation of the Function of ASFV Gene E66L in the Process of Virus Replication and Virulence in Swine.Viruses · 2023Article
- Full genome sequence for the African swine fever virus outbreak in the Dominican Republic in 1980.Scientific reports · 2023Article
- Post-genomic era in agriculture and veterinary science: successful and proposed application of genetic targeting technologies.Frontiers in veterinary science · 2023Review
- A Highly Effective African Swine Fever Virus Vaccine Elicits a Memory T Cell Response in Vaccinated Swine.Pathogens (Basel, Switzerland) · 2022Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene editing of large DNA viruses, such as African swine fever virus (ASFV), has traditionally relied on homologous recombination of a donor plasmid consisting of a reporter cassette with surrounding homologous viral DNA. However, this homologous recombination resulting in the desired modified virus is a rare event. We recently reported the use of CRISPR/Cas9 to edit ASFV. The use of CRISPR/Cas9 to modify the African swine fever virus genome resulted in a fast and relatively easy way to introduce genetic changes. To accomplish this goal we first infect primary swine macrophages with a field isolate, ASFV-G, and transfect with the CRISPR/Cas9 donor plasmid along with a plasmid that will express a specific gRNA that targets our gene to be deleted. By inserting a reporter cassette, we are then able to purify our recombinant virus from the parental by limiting dilution and plaque purification. We previously reported comparing the traditional homologous recombination methodology with CRISPR/Cas9, which resulted in over a 4 log increase in recombination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.